Performance of Turbuhaler® in Patients with Acute Airway Obstruction and COPD, and in Children with Asthma

The dry-powder inhaler (DPI) Turbuhaler® has been on the market for nearly two decades. Products containing terbutaline, formoterol, budesonide, and the combination budesonide/formoterol are widely used by patients with asthma and COPD. Most patients and physicians find Turbuhaler® easy to use, and local side effects are rare. This is thought to arise from the lack of additives or only small amounts in the formulation, in addition to minimal deposition of the drug in the oropharynx and on the vocal cords during inspiration.